BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Wirth S. Current treatment options and response rates in children with chronic hepatitis C. World J Gastroenterol 2012; 18(2): 99-104 [PMID: 22253515 DOI: 10.3748/wjg.v18.i2.99]
URL: https://www.wjgnet.com/1007-9327/full/v18/i2/99.htm
Number Citing Articles
1
Suzan El Naghi, Faten Mahmoud. Study of outcome of naïve and previous nonresponder hepatitis C virus Egyptian children treated with combined therapy of pegylated interferon plus ribavirinEgyptian Liver Journal 2014; 4(3): 87 doi: 10.1097/01.ELX.0000451421.61577.04
2
Eric Druyts, Kristian Thorlund, Ping Wu, Steve Kanters, Sanni Yaya, Curtis L. Cooper, Edward J. Mills. Efficacy and Safety of Pegylated Interferon Alfa-2a or Alfa-2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in Children and Adolescents: A Systematic Review and Meta-analysisClinical Infectious Diseases 2013; 56(7): 961 doi: 10.1093/cid/cis1031
3
Sara K. Smith, Philip Rosenthal. Clearance of Hepatitis C Virus After Fixed‐Dose Combination Ledipasvir/Sofosbuvir in an Adolescent Female With Decompensated CirrhosisJournal of Pediatric Gastroenterology and Nutrition 2016; 63(5): 516 doi: 10.1097/MPG.0000000000001278
4
Samantha Ohmer, Jonathan Honegger. New prospects for the treatment and prevention of hepatitis C in childrenCurrent Opinion in Pediatrics 2016; 28(1): 93 doi: 10.1097/MOP.0000000000000313
5
Etienne M. Sokal. Direct-acting antivirals for paediatric HCV: we got thereNature Reviews Gastroenterology & Hepatology 2017; 14(8): 452 doi: 10.1038/nrgastro.2017.92
6
S. Wirth, Dagmar Schreiber-Dietrich, Christoph F. Dietrich. Aktuelle Therapie der chronischen Hepatitis C bei Kindern und JugendlichenMonatsschrift Kinderheilkunde 2021; 169(6): 534 doi: 10.1007/s00112-021-01122-y
7
Stefan Wirth. Textbook of Pediatric Gastroenterology, Hepatology and Nutrition2022; : 833 doi: 10.1007/978-3-030-80068-0_63
8
Danica E. Kuncio, E. Claire Newbern, Caroline C. Johnson, Kendra M. Viner. Failure to Test and Identify Perinatally Infected Children Born to Hepatitis C Virus–Infected WomenClinical Infectious Diseases 2016; 62(8): 980 doi: 10.1093/cid/ciw026
9
A Bamford, A Turkova, H Lyall, C Foster, N Klein, D Bastiaans, D Burger, S Bernardi, K Butler, E Chiappini, P Clayden, M Della Negra, V Giacomet, C Giaquinto, D Gibb, L Galli, M Hainaut, M Koros, L Marques, E Nastouli, T Niehues, A Noguera‐Julian, P Rojo, C Rudin, HJ Scherpbier, G Tudor‐Williams, SB Welch. Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV‐1 infection 2015: optimizing health in preparation for adult lifeHIV Medicine 2018; 19(1) doi: 10.1111/hiv.12217
10
Stefan Wirth. Textbook of Pediatric Gastroenterology, Hepatology and Nutrition2016; : 681 doi: 10.1007/978-3-319-17169-2_60
11
Karen F. Murray, William F. Balistreri, Sanjay Bansal, Suzanne Whitworth, Helen M. Evans, Regino P. Gonzalez‐Peralta, Jessica Wen, Benedetta Massetto, Kathryn Kersey, Jiang Shao, Kimberly L. Garrison, Bandita Parhy, Diana M. Brainard, Ronen Arnon, Lynette A. Gillis, Maureen M. Jonas, Chuan‐Hao Lin, Michael R. Narkewicz, Kathleen Schwarz, Philip Rosenthal. Safety and Efficacy of Ledipasvir–Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6‐11Hepatology 2018; 68(6): 2158 doi: 10.1002/hep.30123
12
Etienne Nel, Ronald J. Sokol, Donatella Comparcola, Valerio Nobili, Winita Hardikar, Juan Cristóbal Gana, Katia Abarca, Jia‐Feng Wu, Mei‐Hwei Chang, James Kweku Renner. Viral Hepatitis in ChildrenJournal of Pediatric Gastroenterology and Nutrition 2012; 55(5): 500 doi: 10.1097/MPG.0b013e318272aee7
13
Malgorzata Pawlowska. Pegylated IFN-α-2a and ribavirin in the treatment of hepatitis C infection in childrenExpert Opinion on Drug Safety 2015; 14(3): 343 doi: 10.1517/14740338.2015.1005599
14
Yasser K. Rashed, Fatma A. Khalaf, Sobhy E. Kotb. Thyroid disturbances in children treated with combined pegylated interferon-alpha and ribavirin for chronic hepatitis CClinical and Experimental Pediatrics 2020; 63(2): 52 doi: 10.3345/kjp.2018.07150
15
Salahuddin Mahmud, Jahida Gulshan, Md. Belayet Hossain, Madhabi Baidya, Rafia Rashid, Farhana Tasneem, Ahmed Rashidul Hasan, Tanzila Farhana, Mohammed Reaz Mobarak, Md. Jahangir Alam, Syed Shafi Ahmed. Efficiency and safety of sofosbuvir in Bangladeshi children with chronic hepatitis C virus infectioniLIVER 2023; 2(3): 146 doi: 10.1016/j.iliver.2023.06.002
16
Magdalena PLUTA, Maria POKORSKA-ŚPIEWAK, Małgorzata ANISZEWSKA, Zbigniew LEWANDOWSKI, Barbara KOWALIK-MIKOŁAJEWSKA, Magdalena MARCZYŃSKA. Pegylated interferon and ribavirin gone but not forgotten in the era of direct-acting antiviralsMinerva Pediatrics 2022; 74(1) doi: 10.23736/S2724-5276.20.05881-8
17
Hitoshi Tajiri, Yasuhito Tanaka, Tomoko Takano, Mitsuyoshi Suzuki, Daiki Abukawa, Yoko Miyoshi, Toshiaki Shimizu, Stephen Brooks. Association of IL28B polymorphisms with virological response to peginterferon and ribavirin therapy in children and adolescents with chronic hepatitis CHepatology Research 2014; 44(10) doi: 10.1111/hepr.12206
18
Lenka Benova, Susanne F. Awad, F. DeWolfe Miller, Laith J. Abu‐Raddad. Estimation of hepatitis C virus infections resulting from vertical transmission in EgyptHepatology 2015; 61(3): 834 doi: 10.1002/hep.27596
19
Leigh Cervino, Lauren M. Hynicka. Direct-Acting Antivirals to Prevent Vertical Transmission of Viral Hepatitis C: When Is the Optimal Time to Treat?Annals of Pharmacotherapy 2018; 52(11): 1152 doi: 10.1177/1060028018772181
20
Aabha Nagral, Ajay Jhaveri, Smita Sawant, Nirzar Samir Parikh, Nishtha Nagral, Rashid Merchant, Mihir Gandhi. Treatment of Chronic Hepatitis C Infection with Direct Acting Antivirals in Adolescents with Thalassemia MajorThe Indian Journal of Pediatrics 2019; 86(2): 148 doi: 10.1007/s12098-018-2752-7
21
Sarfraz Ahmed, Najeeb Ullah, Sadia Parveen, Ifra Javed, Nur Asyilla Che Jalil, Mogana Das Murtey, Irfan Shahzad Sheikh, Shahroz Khan, Suvash Chandra Ojha, Ke Chen, Jianbo Xiao. Effect of Silymarin as an Adjunct Therapy in Combination with Sofosbuvir and Ribavirin in Hepatitis C Patients: A Miniature Clinical TrialOxidative Medicine and Cellular Longevity 2022; 2022: 1 doi: 10.1155/2022/9199190
22
Haruki Komatsu, Ayano Inui, Tomoyuki Tsunoda, Tsuyoshi Sogo, Tomoo Fujisawa. Association between an IL‐28B genetic polymorphism and the efficacy of the response‐guided pegylated interferon therapy in children with chronic hepatic C infectionHepatology Research 2013; 43(4): 327 doi: 10.1111/j.1872-034X.2012.01087.x
23
Menka M. Sanghvi, Peter J. Hotez, Alan Fenwick. Neglected tropical diseases as a cause of chronic liver disease: the case of Schistosomiasis and Hepatitis C Co‐infections in EgyptLiver International 2013; 33(2): 165 doi: 10.1111/liv.12052
24
Debbie Hartwell, Keith Cooper, Geoff K Frampton, Louise Baxter, Emma Loveman. The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluationHealth Technology Assessment 2014; 18(65): 1 doi: 10.3310/hta18650
25
Tawhida Y Abdel-Ghaffar, Mostafa M Sira, Suzan El Naghi. Hepatitis C genotype 4: The past, present, and futureWorld Journal of Hepatology 2015; 7(28): 2792-2810 doi: 10.4254/wjh.v7.i28.2792
26
Stefan Wirth, Philip Rosenthal, Regino P. Gonzalez‐Peralta, Maureen M. Jonas, William F. Balistreri, Chuan‐Hao Lin, Winita Hardikar, Kathryn Kersey, Benedetta Massetto, Bittoo Kanwar, Diana M. Brainard, Jiang Shao, Evguenia Svarovskaia, Brian Kirby, Ronen Arnon, Karen F. Murray, Kathleen B. Schwarz. Sofosbuvir and ribavirin in adolescents 12‐17 years old with hepatitis C virus genotype 2 or 3 infectionHepatology 2017; 66(4): 1102 doi: 10.1002/hep.29278
27
Juan Francisco Sánchez-Ávila. Mexican Consensus on the Diagnosis and Management of Hepatitis C InfectionAnnals of Hepatology 2015; 14: S7 doi: 10.1016/S1665-2681(19)30815-4
28
Qurratulain Shahood Ahmed, Zehra Fadoo, Kamran Sadiq, Sadaf Altaf. Hepatitis C at presentation in a newly diagnosed infant with B Acute Lymphoblastic LeukemiaPediatric Hematology Oncology Journal 2018; 3(1): 31 doi: 10.1016/j.phoj.2017.11.003
29
Daniele Serranti, Giuseppe Indolfi, Massimo Resti. New treatments for chronic hepatitis C: An overview for paediatriciansWorld Journal of Gastroenterology 2014; 20(43): 15965-15974 doi: 10.3748/wjg.v20.i43.15965
30
Etienne M. Sokal, Pilar Nannini. Chapter 6.1. Pediatric Chronic Hepatitis B and CJournal of Pediatric Gastroenterology and Nutrition 2018; 66(S1) doi: 10.1002/j.1536-4801.2018.tb00053.x
31
Polina German, Anita Mathias, Diana Brainard, Brian P. Kearney. Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis CClinical Pharmacokinetics 2016; 55(11): 1337 doi: 10.1007/s40262-016-0397-0
32
Hanaa El‐Karaksy, Engy Adel Mogahed, Hala Abdullatif, Carolyne Ghobrial, Mona S. El‐Raziky, Nehal El‐Koofy, Mortada El‐Shabrawi, Haytham Ghita, Sherif Baroudy, Sawsan Okasha. Sustained Viral Response in Genotype 4 Chronic Hepatitis C Virus–infected Children and Adolescents Treated With Sofosbuvir/LedipasvirJournal of Pediatric Gastroenterology and Nutrition 2018; 67(5): 626 doi: 10.1097/MPG.0000000000002101
33
Philip Rosenthal, Kathleen B. Schwarz, Regino P. Gonzalez‐Peralta, Chuan‐Hao Lin, Deidre A. Kelly, Scott Nightingale, William F. Balistreri, Sanjay Bansal, Maureen M. Jonas, Benedetta Massetto, Diana M. Brainard, Chia‐Hsiang Hsueh, Jiang Shao, Bandita Parhy, Suzanne Davison, Cornelia Feiterna‐Sperling, Lynette A. Gillis, Giuseppe Indolfi, Etienne M. Sokal, Karen F. Murray, Stefan Wirth. Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 InfectionHepatology 2020; 71(1): 31 doi: 10.1002/hep.30821
34
Sara Domínguez-Rodríguez, Luis Prieto, Carolina Fernández McPhee, Marta Illán-Ramos, José Beceiro, Luis Escosa, Eloy Muñoz, Iciar Olabarrieta, Francisco Javier Regidor, Miguel Ángel Roa, María del Carmen Viñuela Beneítez, Sara Guillén, Maria Luisa Navarro-Gómez, José Tomás Ramos Amador, Jodie Dionne-Odom. Perinatal HCV Transmission Rate in HIV/HCV Coinfected women with access to ART in Madrid, SpainPLOS ONE 2020; 15(4): e0230109 doi: 10.1371/journal.pone.0230109
35
Iraj Shahramian, Kaveh Tabrizian, Mojtaba Delaramnasab, Ali Khosravi Bonjar, Seyed Mohsen Dehghani, Omolbanin Sargazi-Aval, Ali Bazi. A Review on Clinical, Pathophysiological, and Diagnostic Hematological Features in Children With Liver CirrhosisInternational Journal of Basic Science in Medicine 2019; 4(3): 86 doi: 10.15171/ijbsm.2019.17
36
Stefan Wirth, Ralf Bialek, Ulrich Baumann. Pädiatrische Gastroenterologie, Hepatologie und Ernährung2013; : 489 doi: 10.1007/978-3-642-24710-1_18
37
Anu Osinusi, John G. McHutchison. HCV: The Journey from Discovery to a CureTopics in Medicinal Chemistry 2019; 32: 237 doi: 10.1007/7355_2018_48
38
Shivadatta Padhi, Sudhir Maharshi, Gaurav K. Gupta, Kapil Garg, Sandeep Nijhawan. Efficacy and Safety of Direct Acting Antiviral Therapy for Chronic Hepatitis C in Thalassemic ChildrenJournal of Pediatric Hematology/Oncology 2018; 40(7): 511 doi: 10.1097/MPH.0000000000001217
39
Iuri Bastos Pereira, Mair Machado Medeiros de Oliveira, Priscila Brigolini Porfírio Ferreira, Roberta Pereira Coutinho, Lys Eiras Cameron, Isaura Setenta Porto. Avaliação ultraestrutural de agulhas e seu papel no conforto durante a administração subcutânea de medicamentosRevista da Escola de Enfermagem da USP 2018; 52 doi: 10.1590/s1980-220x2017024003307